Loading clinical trials...
Loading clinical trials...
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults (EPACRA-AKI)
Conditions
Interventions
ProNephro AKI (NGAL)
Locations
12
United States
The University of Alabama
Birmingham, Alabama, United States
UC Davis
Sacramento, California, United States
Yale University
New Haven, Connecticut, United States
University of Chicago
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
October 28, 2024
Primary Completion Date
January 30, 2026
Completion Date
January 31, 2026
Last Updated
November 19, 2025
NCT05806645
NCT07472426
NCT07447791
NCT07106151
NCT07418242
NCT05879432
Lead Sponsor
BioPorto Diagnostics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions